Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
Gilead Sciences Announces Completion of Acquisition of CymaBay
2024年3月22日 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the ...
Gilead Sciences Expands Liver Portfolio With Acquisition of …
2024年2月12日 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, Calif., March 22, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics,...
CymaBay Stock Skyrockets After Gilead Snaps Up The Liver …
2024年2月12日 · CymaBay (CBAY) stock rocketed more than 25% Monday after Gilead Sciences (GILD) said it would snap up the liver disease drugmaker for $4.3 billion. Biotech Stocks Are Shooting Higher. Here's How...
Gilead to buy CymaBay for $4.3 bln in bets on liver disease …
2024年2月12日 · Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its...
CymaBay Announces FDA Acceptance of NDA and Priority Review …
NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
CymaBay Announces Closing of Upsized $258.7 Million Public …
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver...
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
2024年2月13日 · Gilead Sciences, Inc. GILD announced that it will acquire clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc. CBAY, for $32.50 per share in cash or a total equity value of $4.3...
CBAY Stock: How CymaBay, With 159% Growth This Year, Is …
2023年9月8日 · Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay Therapeutics ' (CBAY) experimental liver-disease treatment to rivals from Intercept Pharmaceuticals (ICPT) and...